- Home
- NSTS vs EPIX Comparison
NSTS vs EPIX Comparison
Compare NSTS & EPIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSTS
- EPIX
- Stock Information
- Founded
- NSTS 1921
- EPIX 2009
- Country
- NSTS United States
- EPIX Canada
- Employees
- NSTS N/A
- EPIX N/A
- Industry
- NSTS Savings Institutions
- EPIX Biotechnology: Pharmaceutical Preparations
- Sector
- NSTS Finance
- EPIX Health Care
- Exchange
- NSTS Nasdaq
- EPIX Nasdaq
- Market Cap
- NSTS 64.0M
- EPIX 75.9M
- IPO Year
- NSTS N/A
- EPIX N/A
- Fundamental
- Price
- NSTS $11.94
- EPIX $1.93
- Analyst Decision
- NSTS
- EPIX Hold
- Analyst Count
- NSTS 0
- EPIX 3
- Target Price
- NSTS N/A
- EPIX $2.00
- AVG Volume (30 Days)
- NSTS 1.6K
- EPIX 304.7K
- Earning Date
- NSTS 08-14-2025
- EPIX 08-13-2025
- Dividend Yield
- NSTS N/A
- EPIX N/A
- EPS Growth
- NSTS N/A
- EPIX N/A
- EPS
- NSTS N/A
- EPIX N/A
- Revenue
- NSTS $9,435,000.00
- EPIX N/A
- Revenue This Year
- NSTS N/A
- EPIX N/A
- Revenue Next Year
- NSTS N/A
- EPIX N/A
- P/E Ratio
- NSTS N/A
- EPIX N/A
- Revenue Growth
- NSTS 69.39
- EPIX N/A
- 52 Week Low
- NSTS $9.37
- EPIX $1.40
- 52 Week High
- NSTS $13.32
- EPIX $7.88
- Technical
- Relative Strength Index (RSI)
- NSTS 40.59
- EPIX 71.19
- Support Level
- NSTS $12.05
- EPIX $1.90
- Resistance Level
- NSTS $12.17
- EPIX $1.93
- Average True Range (ATR)
- NSTS 0.07
- EPIX 0.01
- MACD
- NSTS -0.01
- EPIX -0.00
- Stochastic Oscillator
- NSTS 0.00
- EPIX 100.00
About NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company was focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It was developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival. Currently, the company has terminated its clinical trials and other studies.